Nyrada (ASX:NYR) Beginning Cash Position : A$3.71 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada Beginning Cash Position?

Nyrada's Beginning Cash Position for the quarter that ended in Dec. 2023 was A$3.71 Mil.

Nyrada's quarterly Beginning Cash Position declined from Dec. 2022 (A$10.82 Mil) to Jun. 2023 (A$9.35 Mil) and declined from Jun. 2023 (A$9.35 Mil) to Dec. 2023 (A$3.71 Mil).

Nyrada's annual Beginning Cash Position increased from Jun. 2021 (A$5.15 Mil) to Jun. 2022 (A$13.75 Mil) but then declined from Jun. 2022 (A$13.75 Mil) to Jun. 2023 (A$10.82 Mil).

Nyrada Beginning Cash Position Historical Data

The historical data trend for Nyrada's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Beginning Cash Position Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Beginning Cash Position

1.10

5.15

13.75

10.82

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial			13.75	11.10	10.82	9.35	3.71

Nyrada Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Nyrada Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Nyrada's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines